Skip to main content
. 2021 Dec 23;7(1):100347. doi: 10.1016/j.esmoop.2021.100347

Figure 2.

Figure 2

(A) The progression-free survival curve of all patients of our cohort. (B) The progression-free survival curve of patients who received any EGFR-TKI-based therapy (either monotherapy or combination therapy; n = 69) versus chemotherapy (n = 35). (C) The progression-free survival curve of four groups: EGFR-TKI monotherapy (n = 48), EGFR-TKI combined with chemotherapy (n = 12), EGFR-TKI combined with crizotinib (n = 9), and chemotherapy (n = 35).

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.